Cancer Cell Journal Publication
Released
Released
Announcement PDF
ASX Announcement
Cancer Cell Journal Publication
29 June 2020 – Race Oncology Limited (ASX: RAC) has become aware of a publication by Su, R et al. in
Cancer Cell in July 2020 entitled “Targeting FTO Supresses Cancer Stem Cell Maintenance and Immune
Invasion” prepared by scientists at the Beckman Research Institute of City of Hope, Los Angeles.
This publication relates to research conducted in relation to Bisantrene, the cancer drug which the
Company is presently investigating in Phase II clinical trials.
The Company was not involved in, or aware of, the research findings of the manuscript. However, the
Company will be evaluating the findings over the coming weeks and months to determine the extent
to which they affect the Company and its own research activities.
As the Company has not been involved in the research referred to in the publication, it cautions
investors not to trade on the basis of this information.
- ENDS About Race Oncology (RAC: ASX)
Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called Bisantrene.
RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast
and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development strategy that involves
parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.
Release authorised by:
Media contact:
John Cullity, Executive Chairman
Jane Lowe, IR Department
John.cullity@raceoncology.com
+61 411 117 774
Jane.lowe@irdepartment.com.au
Race Oncology Ltd ABN 61 149 318 749
Registered office: L40, 140 William St, Melbourne VIC 3004
www.raceoncology.com
Share your feedback
Discover